Microvessel density and thrombospondin-1 (TSP-1) expression were analysed in 42 nonsmall cell lung cancer (NSCLC) specimens and 40 normal lung tissue specimens using immunohistochemistry. Microvessel density was significantly higher and TSP-1 expression significantly lower in NSCLC tissue compared with normal tissue. Significantly lower levels of TSP-1 expression and higher microvessel densities were found in late-stage NSCLC compared with early-stage NSCLC, and in those with lymph node metastasis compared with those without metastasis. A statistically significant inverse correlation was observed between TSP-1 expression and microvessel density in squamous cell carcinoma but not in adenocarcinoma. These results suggest a close relationship between microvessel density and NSCLC tumour progress, and that a high expression of TSP-1 may play an important role in inhibiting tumour occurrence and development. The lack of correlation between microvessel density and TSP-1 expression in adenocarcinoma suggests that the mechanism of tumour inhibition by TSP-1 varies according to histological type.
Introduction
Lung cancer is becoming the leading cause of cancer death worldwide, with most patients dying of tumour recurrence and metastasis. 1 Angiogenesis is essential for cancers to grow and develop, and tumour angiogenesis is tightly regulated by a variety of positive and negative effector molecules. 2 Experimental and clinical evidence suggests that the endogenous angiogenic inhibitor thrombospondin-1 (TSP-1) plays an inhibitory role in tumour cell proliferation and metastasis; 3 the exact mechanism of action is unknown, but it is possible that it may involve inhibition of tumour angiogenesis. 4 In this study, microvessel density and TSP-1 expression were investigated using immunohistochemistry in non-small cell lung cancer (NSCLC) patients. Relationships ZJ Chen, HB Le, YK Zhang et al.
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between the TSP-1 expression level and tumour neovascularization as well as the clinical significance of TSP-1 expression were analysed.
Patients and methods

TISSUE SAMPLES
Samples were obtained from consecutive patients with NSCLC undergoing surgical resection at The First Hospital, Zhoushan City, China between December 2002 and September 2004. As well as samples from the NSCLC lesions, samples of normal lung tissue > 15 cm away from the NSCLC lesions in each patient were excised for examination as controls. Patient characteristics and clinicopathological features were recorded; stages I and II according to the tumour node metastasis (TNM) staging system 5 were defined as early stage and stages III and IV as late stage, for statistical analysis.
Written informed consent was obtained from each patient before entering the study. Ethics approval of the study protocol was provided by the Ethics Committee of The First Hospital, Zhoushan City.
ASSESSMENT OF MICROVESSEL DENSITY
Tissue sections were examined for microvessel density using an immunohistochemical method which has been previously reported. 6 The primary antibody was a CD34 monoclonal antibody (Zhongshan Bio, Beijing, China). The number of microvessels in five high-power fields (magnification ×200) were counted and the mean calculated. All slides were evaluated by three pathologists who were blinded to the nature of the tissue samples.
ASSESSMENT OF TSP-1 EXPRESSION
Expression of TSP-1 was determined in tissue samples using an immunohistochemical method as described previously. 6 The primary antibody was a monoclonal anti-TSP-1 antibody (NeoMarkers Inc., Fremont, CA, USA). Immunoreactivity of TSP-1 was categorized as negative when TSP-1 expression of the interstitial cells of the tumour was weaker than that of normal alveolar tissue in the same section, and it was regarded as positive when TSP-1 expression of the interstitial cells of the tumour was equal to (or stronger than) that of normal alveolar tissue. Each section was evaluated by three independent observers who were blinded to the nature of the tissue samples.
STATISTICAL ANALYSIS
Statistical analyses were performed using SPSS ® version 11.0 software (SPSS Inc, Chicago, IL, USA). Student's t-test was used to compare means from the two groups and the χ 2 test was used to analyse TSP-1 expression and clinicopathological features. A P-value < 0.05 was considered to be statistically significant.
Results
Samples were examined from a total of 42 patients with NSCLC. Control specimens were also obtained from 40 of these patients.
MICROVESSEL DENSITY
Microvessel density in NSCLC tissue was significantly greater than in normal alveolar tissue (P = 0.001; Table 1 ). In addition, microvessel density in late-stage NSCLC was significantly higher than in early-stage disease (P = 0.025) and was also significantly higher (P = 0.009) in patients with lymph node metastasis than in those without lymph node metastasis ( Table 2) . No significant differences in microvessel density were found in relation to age, gender, differentiation or pathological type ( Table 2 ).
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TSP-1 EXPRESSION
Expression of TSP-1 was significantly reduced in NSCLC tissue compared with normal tissue (P = 0.012; Table 1 ). In early stage NSCLC, TSP-1 expression was significantly higher than in late stage NSCLC (P = 0.016), but was significantly lower (P = 0.016) in patients with lymph node metastasis than in those without lymph node metastasis ( Table  2) . No significant differences in TSP-1 expression were found in relation to age, gender, differentiation or pathological type ( Table 2 ).
RELATIONSHIP BETWEEN TSP-1 AND MICROVESSEL DENSITY
No statistically significant association was seen between TSP-1 expression and microvessel density when all NSCLC specimens were analysed together. When considered according to pathological type, a statistically significant inverse correlation was observed between TSP-1 expression and microvessel density in squamous cell carcinoma (P = 0.005) but not in adenocarcinoma (Table 3 ).
Discussion
Neovascularization is vital for tumour development and metastasis. In the present study, rich angiogenesis was seen in the NSCLC tumour lesions, with microvessel density increased in the late TNM stage. In addition, a high microvessel density was associated with metastasis, which suggests a close relationship between microvessel density and tumour progression in NSCLC.
Angiogenesis is thought to be controlled by a balance between angiogenic stimulators and inhibitors. 7 TSP-1 is an endogenous angiogenic inhibitor that has been reported in many tumour types. 8 Decreased TSP-1 expression has been found in lung cancer and this was associated with a poor prognosis. 9 Lee et al. 10 found that transfection of the TSP-1 gene into a murine melanoma and lung metastasis model led to a decrease in microvessel density in the original tumour and lung metastasis tissue; as a result, tumour growth was delayed and survival was significantly prolonged. In contrast, Simantov et al. 11 found that the anti-angiogenic effect of TSP-1 can be inhibited by a specific antibody to TSP-1, suggesting that TSP-1 may act as a defence against tumour growth by inhibiting neovascularization. In the present study, TSP-1 expression was lower in late-stage cases and those with accompanying lymph node metastasis than in early-stage cases and those without lymph node metastasis. This suggests that the expression of TSP-1 is very important in tumour invasion; a high expression of TSP-1 may play an important An inverse correlation between TSP-1 expression and microvessel density was found for squamous cell carcinoma but no correlation was found for adenocarcinoma, which is consistent with the results of Yamaguchi et al. 6 This strongly suggests that the mechanism of tumour inhibition by TSP-1 differs according to histological type in terms of TSP-1 suppressing the development of squamous cell carcinoma through inhibiting tumour angiogenesis, although in adenocarcinoma another type of inhibition may be occurring. Hu et al. 12 reported that no neovascularization occurred in the tumour in some NSCLC cases, with tumour development and progression depending entirely on tumour cell proliferation. It has also been reported that TSP-1 can act by directly inhibiting tumour proliferation, without neovascularization. 13 It is, therefore, possible that TSP-1 suppresses adenocarcinoma progression by direct effects on tumour cell proliferation. The evidence that TSP-1 can inhibit angiogenesis indicates that it may be useful in tumour therapy. A phase I clinical trial evaluating the safety and efficacy of ABT-510, a TSP-1 peptide mimetic, in patients with solid tumours has been published, with no toxicities reported. 14 It is clear, therefore, that the investigation of TSP-1 will continue to provide new insights and suggest new paradigms of angiogenic fine-tuning. Perhaps tumour cells may be induced to secrete high levels of TSP-1, thereby inhibiting tumour growth, angiogenesis and metastasis and improving prognosis. Further research is required to elucidate the role of TSP-1 in tumour growth and its therapeutic potential.
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TABLE 3: Relationship between microvessel density and thrombospondin-1 (TSP-1) expression in non-small cell lung cancer (NSCLC) tissue according to pathological type
